Literature DB >> 3876938

Pharmacokinetics of pirprofen in young volunteers and elderly patients.

L Rooney, M J Kendall, A Main, J Hosie, V A John.   

Abstract

Plasma concentrations of pirprofen were measured in 11 elderly arthritic patients and 6 healthy young volunteers at the beginning and end of 8 days treatment with 400 mg doses twice daily. The mean ages of the two groups were 74.5 and 21.8 years, respectively. There were no statistically significant differences in peak concentrations, times to peak, areas under the curve or terminal elimination half-lives between the groups after single dosing. Repeated dosing increased plasma drug concentrations in both groups but the extent was as predicted from the single dose data. Again there were no statistically significant differences between the groups, although pre-dosing plasma concentrations were higher in the elderly compared with the young individuals. The results of this relatively small study suggest that advancing age and arthritic disease appear to have little influence on the pharmacokinetics of pirprofen and no modification in the dosage recommendation in elderly patients without overt renal or hepatic impairment is indicated.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3876938     DOI: 10.1007/bf00547372

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  20 in total

1.  Increased sensitivity to nitrazepam in old age.

Authors:  C M Castleden; C F George; D Marcer; C Hallett
Journal:  Br Med J       Date:  1977-01-01

2.  A dual approach to the evaluation of the efficacy of a new rheumatoid arthritic agent--pirprofen.

Authors:  M B Maggio-Cavaliere; L Bonus; O B Gum
Journal:  J Clin Pharmacol       Date:  1976-01       Impact factor: 3.126

3.  Pharmacokinetic observations on piroxicam in young adult, middle-aged and elderly patients.

Authors:  A D Woolf; H J Rogers; I D Bradbrook; D Corless
Journal:  Br J Clin Pharmacol       Date:  1983-10       Impact factor: 4.335

4.  The ethics of research in the elderly.

Authors:  M J Denham
Journal:  Age Ageing       Date:  1984-11       Impact factor: 10.668

5.  Effect of age on plasma propranolol levels.

Authors:  R E Schneider; H Bishop; R A Yates; C P Quarterman; M J Kendall
Journal:  Br J Clin Pharmacol       Date:  1980-08       Impact factor: 4.335

6.  The effect of age on the hydroxylation of amylobarbitone sodium in man.

Authors:  R E Irvine; J Grove; P A Toseland; J R Trounce
Journal:  Br J Clin Pharmacol       Date:  1974-02       Impact factor: 4.335

Review 7.  Pharmacokinetics in the elderly.

Authors:  J Crooks; K O'Malley; I H Stevenson
Journal:  Clin Pharmacokinet       Date:  1976       Impact factor: 6.447

8.  Naproxen pharmacokinetics in the elderly.

Authors:  R A Upton; R L Williams; J Kelly; R M Jones
Journal:  Br J Clin Pharmacol       Date:  1984-08       Impact factor: 4.335

9.  Theophylline kinetics in relation to age: the importance of smoking.

Authors:  B Cusack; J G Kelly; J Lavan; J Noel; K O'Malley
Journal:  Br J Clin Pharmacol       Date:  1980-08       Impact factor: 4.335

10.  The pharmacokinetics of diclofenac sodium in patients with active rheumatoid disease.

Authors:  P R Crook; J V Willis; M J Kendall; D B Jack; P D Fowler
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

View more
  8 in total

Review 1.  Hepatic drug metabolism and aging.

Authors:  C Durnas; C M Loi; B J Cusack
Journal:  Clin Pharmacokinet       Date:  1990-11       Impact factor: 6.447

2.  Pharmacokinetics of naproxen in elderly patients.

Authors:  R M McVerry; J Lethbridge; N Martin; S K Mukerjee; T Littler; R Tallis; R Sibeon; M L Orme
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

Review 3.  The pharmacokinetics of non-steroidal anti-inflammatory drugs in the elderly.

Authors:  K W Woodhouse; H Wynne
Journal:  Clin Pharmacokinet       Date:  1987-02       Impact factor: 6.447

4.  Pharmacokinetics of pirprofen and its pyrrol metabolite in elderly patients.

Authors:  F A Rossi; M Ferrero; G E Balladore; L Zecca; F Fraschini; P Ferrario; E Bichisao; G C Monza; V Maresca
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

Review 5.  Pirprofen. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy.

Authors:  P A Todd; R Beresford
Journal:  Drugs       Date:  1986-12       Impact factor: 9.546

6.  Pharmacokinetics of pirprofen in children with juvenile chronic arthritis.

Authors:  F Hallé; F Marfil; A Sioufi; J P Dubois; M Gioud-Paquet; G Lenoir; A M Prieur
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1991 Jan-Mar       Impact factor: 2.441

7.  Influence of renal failure, rheumatoid arthritis and old age on the pharmacokinetics of diflunisal.

Authors:  L O Erikson; E Wåhlin-Boll; I Odar-Cederlöf; L Lindholm; A Melander
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

8.  Influence of age on the enantiomeric disposition of ibuprofen in healthy volunteers.

Authors:  Soo Choon Tan; Bhavesh K Patel; Stephen H D Jackson; Cameron G Swift; Andrew J Hutt
Journal:  Br J Clin Pharmacol       Date:  2003-06       Impact factor: 4.335

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.